Antibody drug conjugates - Trojan horses in the war on cancer

Journal of Pharmacological and Toxicological Methods

Volumn 64, Issue 3, 2011, Pages 207-212

  Iyer, U ^a   Kadambi, V J ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Antibody toxin conjugates; Cancer therapy; Cytotoxin delivery; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIIB 015; BRENTUXIMAB VEDOTIN; BT 062; CYTOTOXIC AGENT; CYTOTOXIN; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IMGN 242; IMGN 388; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MAYTANSINE; MONOCLONAL ANTIBODY; SAR 3419; SGN 75; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN BINDING; B CELL LYMPHOMA; BREAST CANCER; CARCINOMA; CROSS LINKING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTOXINS; NEOPLASMS;

EQUIDAE;

EID: 81955160713     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.07.005     Document Type: Review

References (62)

1. A.C.S. Cancer facts & figures 2010 2010, American Cancer Society.
2. Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Research 1995, 55:2325-2333.
3. Carter P.J. Potent antibody therapeutics by design. Nature Reviews Immunology 2006, 6:343-357.
4. Cassady J.M., Chan K.K., Floss H.G., Leistner E. Recent developments in the maytansinoid antitumor agents. Chemical and Pharmaceutical Bulletin 2004, 52:1-26.
5. Chari R.V.J., Martell B.A., Gross J.L., Cook S.B., Shah S.A., Blattler W.A., et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Research 1992, 52:127-131.
6. Chow K.C., Macdonald T.L., Ross W.E. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: Implications for mechanism of topoisomerase II inhibition. Molecular Pharmacology 1988, 34:467-473.
7. Christiansen J., Rajasekaran A.K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Molecular Cancer Therapeutics 2004, 3:1493-1501.
8. Dijoseph J.F., Dougher M.M., Kalyandrug L.B., Armellino D.C., Boghaert E.R., Hamann P.R., et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against Non-Hodgkin's B-Cell lymphoma. Clinical Cancer Research 2006, 12:242-249.
9. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechonology 2003, 21:778-784.
10. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003, 3:11-22.
11. Ducry L., Stump B. Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chemistry 2010, 21:5-13.
12. Erickson H.K., Park P.U., Widdison W.C., Kovtun Y.V., Garrett L.M., Hoffman K., et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Research 2006, 66:4426-4433.
13. Farid S.S. Process economics of industrial monoclonal antibody manufacture. Journal of Chromatography B 2007, 848:8-18.
14. Firestone R.A., Willner D., Hofstead S.J., King H.D., Kaneko T., Braslawsky G.R., et al. Synthesis and antitumor activity of the immunoconjugate BR96-Dox. Journal of Controlled Release 1996, 39:251-259.
15. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends in Immunology 2004, 25:158-164.
16. Govindan S.V., Goldenberg D.M. Immunoconjugate anticancer therapeutics. Macromolecular Anticancer Therapeutics 2010, 371-391. Humana Press.
17. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clinical Cancer Research 2004, 10:7063-7070.
18. Herbst R.S., Khuri F.R. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treatment Reviews 2003, 29:407-415.
19. Hinman L.M., Hamann P.R., Wallace R., Menendez A.T., Durr F.E., Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Research 1993, 53:3336-3342.
20. Jedema I., Barge R.M.Y., Van Der Velden V.H.J., Nijmeijer B.A., Van Dongen J.J.M., Willemze R., et al. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004, 18:316-325.
21. Jordan M.A., Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Current Opinion in Cell Biology 1998, 10:123-130.
22. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechonology 2008, 26:925-932.
23. Kemshead J.T., Hopkins K. Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: A review. Journal of the Royal Society of Medicine 1993, 86:219-224.
24. Kindler H.L., Tothy Peter K., Wolff Robert, Mccormack Richard A., Abbruzzese James L., Mani Sridhar, et al. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Investigational New Drugs 2005, 23:489-493.
25. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
26. Kovtun Y.V., Audette C.A., Mayo M.F., Jones G.E., Doherty H., Maloney E.K., et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Research 2010, 70:2528-2537.
27. Kovtun Y.V., Audette C.A., Ye Y., Xie H., Ruberti M.F., Phinney S.J. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Research 2006, 66:3214-3221.
28. Lee M.D., Manning J.K., Williams D.R., Kuck N.A., Testa R.T., Borders D.B. Calicheamicins, a novel family of antitumor antibiotics. Journal of Antibiotics 1989, 42:1070-1087.
29. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., et al. Targeting HER2-Positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Research 2008, 68:9280-9290.
30. Liu C., Tadayoni B.M., Bourret L.A., Mattocks K.M., Derr S.M., Widdison W.C., et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:8618-8623.
31. Manshouri T., Do K.-A., Wang X., Giles F.J., O'brien S.M., Saffer H., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507-2513.
32. Markman M. Managing taxane toxicities. Supportive Care in Cancer 2003, 11:144-147.
33. Matsui H.T.A., Naito K., Shinjo K., Shigeno K., Maekawa M., Yamakawa Y., et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002, 16:813-819.
34. McDonagh C.F., Turcott E., Westendorf L., Webster J.B., Alley S.C., Kim K. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Engineering Design & Selection 2006, 19:299-307.
35. Mosure K.W., Henderson A.J., Klunk L.J., Knipe J.O. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemotherapy and Pharmacology 1997, 40:251-258.
36. Nicolaou K.C., Smith A.L. Molecular design, chemical synthesis, and biological action of enediynes. Accounts of Chemical Research 1992, 25:497-503.
37. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Reviews. Cancer 2004, 4:592-603.
38. Okeley N.M., Miyamoto J.B., Zhang X., Sanderson R.J., Benjamin D.R., Sievers E.L., et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clinical Cancer Research 2010, 16:888-897.
39. Panchal R.G. Novel therapeutic strategies to selectively kill cancer cells. Biochemical Pharmacology 1998, 55:247-252.
40. Perez E.A., Hillman David W., Fishkin Paul A., Krook James E., Tan Winston W., Kuriakose Phillip A., et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Investigational New Drugs 2005, 23:257-261.
41. Polson A.G., Williams M., Gray A.M., Fuji R.N., Poon K.A., McBride J. Anti-CD22-MCC-DM1: An antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010, 24:1566-1573.
42. Reichert J.M. Antibody-based therapeutics to watch in 2011. MAbs 2010, 3:76-98.
43. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nature Biotechonology 2005, 23:1073-1078.
44. Riechelmann H., Sauter A., Golze W., Hanft G., Schroen C., Hoermann K., et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncology 2008, 44:823-829.
45. Ryan M.C., Kostner H., Gordon K.A., Duniho S., Sutherland M.K., Yu C., et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. British Journal of Cancer 2010, 103:676-684.
46. Saleh M.N., Sugarman S., Murray J., Ostroff J.B., Healey D., Jones D., et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y - Expressing epithelial tumors. Journal of Clinical Oncology 2000, 18:2282-2292.
47. Scolnik P.A. mAbs: A business perspective. MAbs 2009, 2:179-184.
48. Scott C.T. The problem with potency. Nature Biotechonology 2005, 23:1037-1039.
49. Selenko N., Majdic O., Jäger U., Sillaber C., Stöckl J., Knapp W. Cross-priming of cytotoxic t cells promoted by apoptosis-inducing tumor cell reactive antibodies. Journal of Clinical Immunology 2002, 22:124-130.
50. Senter P.D. Potent antibody drug conjugates for cancer therapy. Current Opinion in Chemical Biology 2009, 13:235-244.
51. Singh R., Erickson H.K. Antibody-cytotoxic agent conjugates: preparation and characterization. Methods in Molecular Biology 2009, 525:1-23. SpringerLink.
52. Sjogren H.O., Isaksson M., Willner D., Hellstrom I., Hellstram K.E., Trail P.A. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Research 1997, 57:4530-4536.
53. Sutherland M.S., Sanderson R.J., Gordon K.A., Andreyka J., Cerveny C.G., Yu C., et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. Journal of Biological Chemistry 2006, 281:10540-10547.
54. Takeshita A., Shinjo K., Yamakage N., Ono T., Hirano I., Matsui H., et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. British Journal of Haematology 2009, 146:34-43.
55. Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N.F., Watson, et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Research 1987, 47:5924-5931.
56. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. Journal of Clinical Oncology 1999, 17:478.
57. Van Der Velden V.H.J., Boeckx N., Jedema I., Te Marvelde J.G., Hoogeveen P.G., Boogaerts M., et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg[reg]) treatment in acute myeloid leukemia patients. Leukemia 2004, 18:983-988.
58. Van Meerten T., Van Rijn R.S., Hol S., Hagenbeek A., Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical Cancer Research 2006, 12:4027-4035.
59. Vater C.A., Goldmacher V.S. Antibody-cytotoxic compound conjugates for oncology. Macromolecular Anticancer Therapeutics 2010, 331-369. Humana Press.
60. Walter R.B., Raden B.W., Kamikura D.M., Cooper J.A., Bernstein I.D. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005, 105:1295-1302.
61. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nature Reviews Immunology 2010, 10:317-327.
62. Wu A.M., Senter P.D. Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechonology 2005, 23:1137-1146.